ANRO Stock Price
Alto Neuroscience, Inc.
ANRO stock price is $24.03 (+2.17% on the day), giving Alto Neuroscience, Inc. a market cap of $922.97M. Below are the price chart, the MarketXLS Rank, the company profile and the latest news.
ANRO Stock Overview
- Price
- $24.03
- Previous close
- $23.52
- Open
- $23.03
- Market cap
- $922.97M
- P/E ratio
- -14.6
- 52-week range
- $5.22 - $37.48
- 1-year price target
- $37.67
- Sector
- Healthcare
- Industry
- Biotechnology
- Exchange
- NYE
- MarketXLS Rank
- 39
About Alto Neuroscience, Inc.
Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company in the United States. The company's product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with bipolar depression (BPD). It develops ALTO-300, a small molecule melatonergic agonist and serotonergic antagonist with antidepressant properties which is in phase 2b clinical trial to treat patients with major depressive disorder (MDD); ALTO-101, a novel small molecule phosphodiesterase 4 inhibitor which is in phase 2 proof-of-concept (POC) trial for the treatment of cognitive impairment associated with schizophrenia; ALTO-203, a novel small-molecule histamine H3 receptor inverse agonist which is in phase 2 POC trial to treat patients with MDD and higher levels of anhedonia; and ALTO-202, an investigational orally bioavailable antagonist of the GluN2B subunit of the NMDA receptor which is in phase 1 clinical trial for the treatment of MDD. The company was incorporated in 2019 and is headquartered in Mountain View, California.
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | ANRO | $24.03 | +2.2% | 409.76K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |